{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:49:53Z","timestamp":1782229793432,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.7759\/cureus.111363","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:30:26Z","timestamp":1782228626000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Faisal A","family":"Aljulajil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unaib","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S001","article-title":"1. Improving care and promoting health in populations: standards of care in diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. 1. Improving care and promoting health in populations: standards of care in diabetes-2023. Diabetes Care. 2023, 46:S10-8. 10.2337\/dc23-S001","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar N","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, et al.. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010, 375:2215-22. 10.1016\/S0140-6736(10)60484-9","journal-title":"Lancet"},{"key":"ref3","unstructured":"International Diabetes Federation. (2024). Accessed. June 7, 2026: https:\/\/www.diabetesatlas.org."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022, 65:1925-66. 10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al.. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015, 38:140-9. 10.2337\/dc14-2441","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann AJ","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al.. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018, 41:258-66. 10.2337\/dc17-0417","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda VR","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al.. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:355-66. 10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30024-x","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley RE","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al.. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018, 6:275-86. 10.1016\/s2213-8587(18)30024-x","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn MS","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al.. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020, 46:100-9. 10.1016\/j.diabet.2019.101117","journal-title":"Diabetes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1432","article-title":"Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis","volume":"164","author":"Zaccardi F","year":"2016","unstructured":"Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016, 164:102-13. 10.7326\/M15-1432","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0428-y","article-title":"A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1-2 oral antidiabetic drugs","volume":"9","author":"Witkowski M","year":"2018","unstructured":"Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1-2 oral antidiabetic drugs. Diabetes Ther. 2018, 9:1233-51. 10.1007\/s13300-018-0428-y","journal-title":"Diabetes Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis P","year":"2018","unstructured":"Andreadis P, Karagiannis T, Malandris K, et al.. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018, 20:2255-63. 10.1111\/dom.13361","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.3. (2022). Accessed. June 7, 2026: https:\/\/training.cochrane.org\/handbook."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau J","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015, 58:7370-80. 10.1021\/acs.jmedchem.5b00726","journal-title":"J Med Chem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505379-efficacy-and-safety-of-once-weekly-semaglutide-versus-basal-insulin-and-other-glp-1-receptor-agonists-in-adults-with-type-2-diabetes-uncontrolled-on-oral-antidiabetic-drugs-a-systematic-review-and-pairwise-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:30:35Z","timestamp":1782228635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505379-efficacy-and-safety-of-once-weekly-semaglutide-versus-basal-insulin-and-other-glp-1-receptor-agonists-in-adults-with-type-2-diabetes-uncontrolled-on-oral-antidiabetic-drugs-a-systematic-review-and-pairwise-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.111363","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}